Barclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most promising future stocks according to Wall Street analysts. In a report released on August 13, Gena Wang from Barclays maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), with a price target of $86.00.

The rating update came after BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported its fiscal Q2 2025 results on August 4, with total revenues reaching $825 million, up 16% year-over-year and up 17% at constant currency year-over-year.

GAAP diluted earnings per share (EPS) for the quarter was $1.23, up 124% year-over-year, while non-GAAP diluted EPS reached $1.44, up 50% year-over-year.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.